Bicycle Therapeutics plc reported fourth‑quarter 2025 revenue of $47.96 million, a 1,200 % year‑over‑year increase from $3.71 million in Q4 2024. The jump was driven almost entirely by collaboration revenue, which rose from $35.28 million to $72.59 million, reflecting strong demand from partners for the company’s technology platform.
The quarter ended with a net loss of $0.29 per share, beating the consensus estimate of a $1.00 loss. The loss narrowed from $0.75 per share in Q4 2024 and $0.85 per share in Q3 2025, underscoring the company’s progress in cost control and the impact of the 30 % workforce reduction announced earlier in the year.
Cash and cash equivalents stood at $628 million as of December 31 2025. The company recorded a total severance and related charges of $5.3 million, higher than the $4.1 million initially reported, reflecting the full scope of the workforce reduction. The cash balance is expected to support operations through the late 2020s, with a runway that extends into 2030 after the cost‑cutting measures.
On a full‑year basis, Bicycle posted a net loss of $218.96 million, or $3.16 per share. The loss reflects continued investment in research and development, despite the revenue growth and margin improvements seen in the quarter.
Management reiterated a strategic shift that deprioritizes the internal development of the zelenectide pevedotin program following regulatory feedback on the Duravelo‑2 trial. The company is now concentrating on its BT5528 program and a portfolio of radioconjugates, positioning itself for a more differentiated pipeline and potential future approvals.
Collaboration revenue growth has become a key tailwind, with the company’s technology platform attracting new partners and expanding existing agreements. The strong revenue beat, combined with disciplined cost management, has improved operating leverage, even as the company continues to invest heavily in its pipeline.
Looking forward, management emphasized the importance of conserving cash and maintaining flexibility. The company’s guidance indicates confidence in sustaining the extended runway, while the strategic realignment signals a focus on high‑potential assets that could drive future revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.